Evolving Treatment Landscape of EoE: Applying the Latest Evidence to Optimize Care

Evolving Treatment Landscape of EoE: Applying the Latest Evidence to Optimize Care is organized by Integrity Continuing Education Inc..

Release date: 05- 04- 2023
Expiration date: 05- 04- 2024

Description:
Program Overview:
Eosinophilic esophagitis (EoE) is a chronic Type 2 inflammatory disease that affects approximately 41 in 100,000 Americans and is associated with a significant clinical and psychosocial burden. EoE is characterized by accumulation of eosinophils, basophils, and mast cells in the esophagus, and when poorly controlled leads to remodeling, narrowing, and fibrosis. Early and accurate diagnosis is crucial for guiding treatment and preventing potentially irreversible esophageal damage. Historically, treatment options have been comprised of dietary restriction, esophageal dilation, proton pump inhibitors, and corticosteroids, all of which often result in suboptimal responses. However, recent advances in understanding of the pathogenesis of EoE have driven the development of novel therapies specifically targeted at various immune mediators. One of these agents, the anti-IL-4/IL-13 dupilumab, became the first FDA-approved treatment for EoE earlier this year.
Join our esteemed faculty as they discuss key strategies to improve the outcomes of patients with EoE. Topics will include early diagnosis, recent clinical trial data regarding new and emerging therapies, and evolving evidence-based recommendations for treatment.

Learning Objectives:
Upon completion of this educational activity, participants should be able to:
• Apply knowledge of the clinical manifestations of EoE to improve evaluation and diagnosis of patients and prevent further damage to the esophagus
• Summarize the pathophysiologic mechanisms of EoE and their rationale as treatment targets for EoE
• Compare clinical profiles, evidence for use, and approval status of medications used in the treatment of patients with EoE
• Utilize clinical evidence to individualize treatment and engage in shared decision making for patients with EoE

Additional details will be posted as soon as information is available.